{
    "title": "Melatonin interacts with Vitamin D in Multiple Sclerosis patients",
    "slug": "melatonin-interacts-with-vitamin-d-in-multiple-sclerosis-patients",
    "aliases": [
        "/Melatonin+interacts+with+Vitamin+D+in+Multiple+Sclerosis+patients",
        "/4355"
    ],
    "tiki_page_id": 4355,
    "date": "2013-07-21",
    "categories": [
        "Multiple Sclerosis"
    ],
    "tags": [
        "Multiple Sclerosis",
        "autoimmune",
        "brain",
        "cognitive",
        "dosage",
        "high dose",
        "immunity",
        "intervention",
        "multiple sclerosis",
        "therapeutic intervention",
        "vitamin d"
    ]
}


#### Latitude, Vitamin D, Melatonin, and Gut Microbiota Act in Concert to Initiate Multiple Sclerosis:  
 A New Mechanistic Pathway - 2018

 **See [A Multiple Sclerosis hypothesis supported by EAE data – Oct 2018](/posts/a-multiple-sclerosis-hypothesis-supported-by-eae-data)** 

---

#### Disruption of melatonin circadian rhythm production is related to multiple sclerosis severity: A preliminary study - 2015

 **"In conclusion, disruption of melatonin circadian rhythm production is frequent among RRMS patients and seemingly related to higher disability and fatigue scores" &nbsp; &nbsp;  [doi: 10.1016/j.jns.2015.03.040](https://doi.org/10.1016/j.jns.2015.03.040)** 

---

#### The influence of vitamin D supplementation on melatonin status in patients with multiple sclerosis - July 2013

 **[Brain, Behavior, and Immunity,](http://www.sciencedirect.com/science/journal/08891591)[Volume 32](http://www.sciencedirect.com/science/journal/08891591/32/supp/C), August 2013, Pages 180–185** 

* [Daniel Golan](http://www.sciencedirect.com/science/article/pii/S0889159113001785#){ANAME()}baf030|<sup>a</sup>{ANAME}<sup>, </sup>{ANAME()}baf010|<sup>b</sup>{ANAME},

* [Elsebeth Staun-Ram](http://www.sciencedirect.com/science/article/pii/S0889159113001785#)[<sup>a</sup>](http://www.sciencedirect.com/science/article/pii/S0889159113001785#af030),

* [Lea Glass-Marmor](http://www.sciencedirect.com/science/article/pii/S0889159113001785#)[<sup>a</sup>](http://www.sciencedirect.com/science/article/pii/S0889159113001785#af030),

* [Idit Lavi](http://www.sciencedirect.com/science/article/pii/S0889159113001785#){ANAME()}baf020|<sup>d</sup>{ANAME},

* [Orit Rozenberg](http://www.sciencedirect.com/science/article/pii/S0889159113001785#){ANAME()}baf015|<sup>c</sup>{ANAME},

* [Sara Dishon](http://www.sciencedirect.com/science/article/pii/S0889159113001785#)[<sup>a</sup>](http://www.sciencedirect.com/science/article/pii/S0889159113001785#af030),

* [Mira Barak](http://www.sciencedirect.com/science/article/pii/S0889159113001785#)[<sup>c</sup>](http://www.sciencedirect.com/science/article/pii/S0889159113001785#af015),

* [Sophia Ish-Shalom](http://www.sciencedirect.com/science/article/pii/S0889159113001785#){ANAME()}baf025|<sup>e</sup>{ANAME},

* [Ariel Miller](http://www.sciencedirect.com/science/article/pii/S0889159113001785#)[<sup>a</sup>](http://www.sciencedirect.com/science/article/pii/S0889159113001785#af030)<sup>, </sup>[<sup>e</sup>](http://www.sciencedirect.com/science/article/pii/S0889159113001785#af025)<sup>, </sup>{ANAME()}bcor1|<img src="http://cdn.els-cdn.com/sd/entities/REcor.gif" alt="image">{ANAME}<sup>, </sup><span>[mailto:millera@tx.technion.ac.il]</span><sup>, </sup><span>[mailto:milleras@netvision.net.il]</span>

* <sup>a</sup>Division of Neuroimmunology & Multiple Sclerosis Center, Carmel Medical Center, Haifa, Israel

* <sup>b</sup>Department of Neurology, Carmel Medical Center, Haifa, Israel

* <sup>c</sup>Central Laboratory of Haifa and Western Galilee, Clalit Health Services, Haifa, Israel

* <sup>d</sup>Department of Community Medicine & Epidemiology, Carmel Medical Center, Haifa, Israel

* <sup>e</sup>Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel

* [http://dx.doi.org/10.1016/j.bbi.2013.04.010](http://dx.doi.org/10.1016/j.bbi.2013.04.010), [How to Cite or Link Using DOI](http://www.sciencedirect.com/science/help/doi.htm)

*  **Note: Most Hyperlinks on this page do not work** 

---

## Highlight

;• Melatonin secretion is negatively correlated with alterations in serum 25-OH-D, suggesting cross-regulation of the two light-dependent immunomodulators.

---

## Abstract

#### Background

Multiple sclerosis (MS) incidence is higher in geographic regions with less sunlight exposure. Both vitamin D and melatonin are essential mediators of the effect of sunlight in health, and as such are candidates to play a key role in MS. We hypothesized that vitamin D and melatonin may have related influences in patients with MS.

#### Methods

In a randomized, double blind study of 40 IFN-β treated MS patients, 21 patients were assigned to 800 IU of vitamin D3 per day (low dose), while 19 patients received 4,370 IU vitamin D3 per day (high dose) for one year. Serum 25-hydroxy-vitamin-D (25-OH-D) and nighttime urine melatonin metabolite, 6-sulphatoxy-melatonin (6-SMT), were measured at baseline, 3 months and 1 year from enrolment.

#### Results

After 3 months supplementation, 25-OH-D levels increased and nighttime melatonin secretion decreased significantly in the high dose group, but not in the low dose group. After 1 year, a decrease in 25-OH-D levels, accompanied by an increase of urine nighttime 6-SMT were observed in the high dose group. Percent change in serum 25-OH-D was significantly and negatively correlated with percent change in urine 6-SMT after 3 months and between 3 months to 1 year. 25-OH-D levels by the end of the study were significantly and negatively correlated to BMI.

#### Conclusions

Melatonin secretion is negatively correlated with alterations in serum 25-OH-D in IFN-β treated patients with MS. The finding suggests that melatonin should be considered as a potential mediator of vitamin D neuro-immunomodulatory effects in patients with MS.

## Keywords

* Chronotherapy;

* Interferon-β;

* Light;

* Melatonin;

* Multiple sclerosis;

* Neurohormone;

* Vitamin D